Sildenafil and vardenafil are two prescription PDE5 inhibitors used for erectile dysfunction, usually in as-needed ED regimens. Their similarities can make comparison tempting, but a choice depends on labeled dosing, medical history, possible meal effects, product availability and drug interactions rather than on claims that one always acts faster or produces a stronger erection.
Vardenafil has a particularly important distinction: warnings related to QT prolongation and certain antiarrhythmic medicines. It also exists in separately labeled orally disintegrating products whose 10 mg strength is not interchangeable with a 10 mg film-coated tablet. Sildenafil ED tablets and vardenafil tablets each have their own FDA-approved product and pharmacokinetic records.
This is an ingredient-level clinical comparison, not a historical brand article or a pharmacy ranking. For vardenafil product identity, see the vardenafil overview; for sildenafil use, see the sildenafil overview. The original U.S. Levitra and Staxyn brands have been discontinued, which does not remove the need to verify individual approved generics.
Both drugs support the cGMP-mediated erectile response when sexual stimulation is present. Neither induces an automatic erection or cures the underlying cause of ED, and both require a clinical assessment before prescribing.
Because both are PDE5 inhibitors, taking them together does not provide a medically established shortcut to improved results. Their active ingredients, approved doses and interactions differ; a pharmacist should dispense the formulation specified by a valid prescription.
The table separates ordinary film-coated vardenafil tablets from the distinctly labeled ODT. It does not equate onset claims, peak concentration and erectile response, or suggest dose equivalence across drugs.
A clinical comparison should rely on the actual U.S. ED product instructions, not the name Levitra in an old search result or non-FDA-approved imported brands.
| Characteristic | Sildenafil ED tablets | Vardenafil ED film-coated tablets |
|---|---|---|
| Available conventional strengths | 25, 50 and 100 mg | 2.5, 5, 10 and 20 mg labeled strengths |
| Typical label timing | Often about one hour before activity | Approximately one hour before activity |
| Meal considerations | High-fat meal delays absorption | High-fat meal may reduce peak exposure; specific data differ |
| QT-related warning | Not the same vardenafil-specific label warning | Specific QT precautions and antiarrhythmic concerns |
| Separate ODT | Not part of this conventional-tablet comparison | 10 mg ODT has distinct, noninterchangeable labeling |
| Former U.S. brand | Viagra is separately identifiable | Levitra original brand discontinued |
Some studies describe early responses to either medicine, but clinical outcomes depend on trial design, time points, stimulation and the selected population. Peak plasma concentrations do not map one-to-one to the first successful sexual event, and a result from unrelated studies cannot prove superiority.
Patients should discuss realistic timing expectations based on their prescribed product. The sildenafil onset and vardenafil onset guides clarify what label-based timing means for each ingredient.
A high-fat meal delays sildenafil peak exposure relative to fasting conditions. Vardenafil film-coated labeling also discusses food effects on peak concentration; these depend on meal composition and the specific measured endpoint. Neither finding should be simplified into an absolute prohibition on taking tablets with food.
ODT has its own instructions and may be taken with or without food; importing film-coated data into an ODT discussion can be wrong. Vardenafil meal considerations and sildenafil and food give the separate analyses.
Vardenafil prescribing information addresses QT interval prolongation and cautions involving congenital long-QT syndrome and certain antiarrhythmic drugs, including class IA and class III agents. This is more specific than a generic statement that all PDE5 inhibitors have the same heart-related concerns.
A clinician should review cardiac diagnoses, ECG-related history when relevant and the full medication list. The warning is not a reason for a patient to conclude that sildenafil is automatically suitable instead: both require cardiovascular and interaction assessment.
A 10 mg orally disintegrating vardenafil tablet has distinct pharmacokinetic exposure from a 10 mg film-coated vardenafil tablet and is explicitly not interchangeable with it. That formulation-specific issue must be resolved before the pharmacist supplies a product.
ODT is neither an approved faster-sildenafil formulation nor an excuse for dose-for-dose swapping. For actual patient administration requirements, see the vardenafil ODT guide.
Both sildenafil and vardenafil are contraindicated with organic nitrates and riociguat. CYP3A4 inhibitors, alpha-blockers and blood-pressure treatments require review, although label instructions differ by product. Urgent symptoms such as chest pain, sudden hearing or sight changes, and erections lasting more than four hours need medical attention.
An emergency care team must be told which ED medicine was taken. Do not perform self-managed nitrate waiting-period calculations or combine these medicines to overcome perceived inadequate response.
Original Levitra and Staxyn U.S. brand presentations were discontinued, whereas separately approved generic vardenafil products remain a distinct regulatory category. Pfizer’s Viagra is a named sildenafil brand, while generic sildenafil applications are separate products.
Brand-name search volume does not establish pharmacy inventory or product equivalence. The Levitra historical guide addresses its discontinuation; the generic vardenafil guide addresses current approval checks.
The complete cost of treatment depends on precise formulation, strength, quantity, insurance plan and dispensing charges. If a comparison switches between branded sildenafil and generic vardenafil, it is partly a brand/generic comparison rather than a pure ingredient comparison.
Ask a licensed pharmacist for current all-in quotes for clinically appropriate prescriptions, using the same defined payment terms. Sildenafil cost factors and vardenafil cost factors explain how to make such inquiries.
Explain past responses to ED treatment, timing needs, usual meal routines, cardiac or QT history, concurrent medicines and any concern with swallowing or dosage forms. These details allow a clinician to decide whether a medicine is appropriate and which label applies.
If someone is already using one PDE5 inhibitor, do not add or replace it independently. The safest comparison ends with an appropriately prescribed, correctly identified medicine rather than a claim that one ingredient wins every category.
No. They are distinct prescription PDE5 inhibitors with related mechanisms but different labels and precautions.
Neither is reliably faster for everyone. Trial timing and pharmacokinetic measurements are not guarantees of individual response.
Yes. Neither automatically causes an erection in the absence of sexual stimulation.
Vardenafil has specific label cautions involving QT prolongation, inherited long-QT conditions and certain antiarrhythmic drugs.
No. The ODT has distinct exposure and cannot automatically replace a film-coated 10 mg tablet.
High-fat meals can alter the absorption of sildenafil and film-coated vardenafil, with different label-specific findings.
Do not combine them without explicit medical direction; both are PDE5 inhibitors and interactions and adverse effects may be increased.
The original U.S. Levitra brand was discontinued. Approved generic vardenafil product status must be checked separately.